Literature DB >> 21365411

Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast.

Michitaka Honda1, Shigehira Saji, Shin-ichiro Horiguchi, Eiji Suzuki, Tomoyuki Aruga, Kazumi Horiguchi, Dai Kitagawa, Susumu Sekine, Nobuaki Funata, Masakazu Toi, Katsumasa Kuroi.   

Abstract

PURPOSE: Primary squamous cell carcinoma (SCC) and metaplastic squamous cell carcinoma (MSCC) are rare types of breast cancer with specific histological features. They are characterized by rapid progression, a tendency toward cyst formation, and negativity for hormone receptors. Many studies have concluded that SCC of the breast carries a poor prognosis, based on the fact that conventional chemotherapy for ductal carcinoma of the breast is ineffective against SCC. This is a retrospective study of patients in a single center with SCC or MSCC.
METHODS: We searched the records of the Tokyo Metropolitan Komagome Hospital for patients diagnosed with breast SCC or MSCC between 1979 and 2006. Squamous cell carcinoma was diagnosed when 100% of the malignant cells showed a squamous component (pure SCC) and MSCC was diagnosed when more than 50% of the malignant cells showed a squamous component. We analyzed the clinicopathological features, treatment methods, and outcomes of these patients.
RESULTS: We identified 10 (0.28%) patients with SCC or MSCC from among 3565 patients with malignant breast tumors treated at our hospital during this period. Nine patients had adenocarcinoma with squamous metaplasia, and one had pure SCC. Ultrasound showed a central cystic-necrotic component in seven tumors, and all of the tumors were negative for hormone receptors and HER2. Recurrence developed in two patients with lymph node metastasis, but not in the other eight patients. The 5-year survival rate and median survival time were 85.7% and 97 months, respectively.
CONCLUSIONS: Squamous cell carcinoma or MSCC of the breast with features of the triple-negative subtype seems to be associated with a poor prognosis; however, nodenegative patients are likely to have a favorable prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21365411     DOI: 10.1007/s00595-009-4276-2

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  Squamous cell carcinoma of the breast.

Authors:  Bryan T Hennessy; Savitri Krishnamurthy; Sharon Giordano; Thomas A Buchholz; Shu W Kau; Zhigang Duan; Vicente Valero; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

2.  Squamous cell carcinoma of the breast in the form of an intracystic tumor.

Authors:  Takashi Shigekawa; Hitoshi Tsuda; Kazuhiko Sato; Shigeto Ueda; Hideki Asakawa; Rena Shigenaga; Hoshio Hiraide; Hidetaka Mochizuki
Journal:  Breast Cancer       Date:  2007       Impact factor: 4.239

3.  Recurrent squamous cell carcinoma of the breast with undifferentiated features: report of a case.

Authors:  Hiroyuki Miura; Osamu Taira; Shunsuke Hiraguri; Junichi Maeda; Harubumi Kato
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

4.  [A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].

Authors:  Kiyoshi Hiramatsu; Kenji Kato; Akihiro Hirata; Hideki Matsuba; Tomohiro Hara; Takaaki Ito; Taishi Miyata; Takashi Akagawa; Yasushi Kutsuna; Yuichi Machiki; Susumu Fujioka
Journal:  Gan To Kagaku Ryoho       Date:  2007-03

5.  Squamous cell carcinoma of the breast.

Authors:  I Aparicio; A Martínez; G Hernández; D Hardisson; J De Santiago
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-05-03       Impact factor: 2.435

6.  Squamous cell carcinoma of the breast: a clinicopathologic analysis of eight cases and review of the literature.

Authors:  J W Eggers; T M Chesney
Journal:  Hum Pathol       Date:  1984-06       Impact factor: 3.466

7.  Primary squamous cell carcinoma of the breast.

Authors:  S Toikkanen
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

8.  Squamous cell carcinoma of the breast.

Authors:  F Cardoso; C Leal; A Meira; R Azevedo; M J Mauricio; J M Leal da Silva; C Lopes; E Pinto Ferreira
Journal:  Breast       Date:  2000-12       Impact factor: 4.380

9.  Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy.

Authors:  D Dejager; P N Redlich; A M Dayer; H L Davis; R A Komorowski
Journal:  J Surg Oncol       Date:  1995-07       Impact factor: 3.454

10.  Primary squamous cell carcinoma of the breast.

Authors:  K Brack; P C G I Ramaekers; W A A Tjalma
Journal:  Eur J Gynaecol Oncol       Date:  2003       Impact factor: 0.196

View more
  5 in total

1.  Natural history of metaplastic squamous cell breast cancer: a case report and literature review on surgical management.

Authors:  Geok-Hoon Lim; Hannah Angela Acosta; Mihir Ananta Gudi
Journal:  Gland Surg       Date:  2017-12

2.  Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression.

Authors:  Ruixue Lei; Lanfang Miao
Journal:  Cancer Biol Ther       Date:  2020-11-12       Impact factor: 4.742

3.  Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.

Authors:  Lisa D Volk-Draper; Sandeep Rajput; Kelly L Hall; Andrew Wilber; Sophia Ran
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

4.  Effect of postoperative radiotherapy for squamous cell cancer of the breast in a surveillance epidemiology and end results population-based study.

Authors:  San-Gang Wu; Jia-Yuan Sun; Wen-Ming Liu; Feng-Yan Li; Huan-Xin Lin; Zhen-Yu He
Journal:  Oncotarget       Date:  2016-03-01

5.  SOX10 - A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma.

Authors:  Jialin Qi; Zhenmin Hu; Heng Xiao; Ruijie Liu; Wei Guo; Zhichun Yang; Kewen Ma; Shitong Su; Ping Tang; Xunjian Zhou; Jianhua Zhou; Kuansong Wang
Journal:  Cancer Manag Res       Date:  2020-05-28       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.